Senseonics Holdings Inc. (NASDAQ: SENS) announced the commencement of an $80 million underwritten public offering of common stock and pre-funded warrants. The medical technology company, which develops implantable continuous glucose monitoring systems for diabetes patients, will offer shares and warrants to certain investors as an alternative to stock purchases.

The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the total shares offered. Pre-funded warrants will not be listed on any securities exchange. TD Cowen and Barclays serve as joint book-running managers, while Mizuho and Lake Street act as bookrunners for the offering.

Senseonics intends to use net proceeds to fund the ongoing launch of its Eversense 365 product and continued development of pipeline products, along with working capital and general corporate purposes. The offering is being conducted under a shelf registration statement filed with the Securities and Exchange Commission that became effective in August 2025.

The proposed offering remains subject to market and other conditions, with no assurance regarding completion timing or final terms. A preliminary prospectus supplement will be filed with the SEC and made available through the agency's website.

Senseonics develops glucose monitoring systems that include a sensor inserted under the skin communicating with a smart transmitter. The system automatically sends glucose data every five minutes to a smartphone application.